We are happy to announce that we finished patient recruitment in Arcagen. Around 1000 patients with one of ten different rare cancers entered the project in three years.

Arcagen looks for changes in the genes that drive the development and progression of rare cancers. We strive to find out about these changes because they can be targets for cancer medicines that work better and cause less side effects than the ones used today. Such was the need for this information, that soon after the launch of the project, hospitals all over Europe quickly joined and eagerly entered their patients.

What an achievement! At EORTC, we are delighted to have been part of this effort and the improvement in the care of cancer patients that it could bring. The success was only possible due to our incredible network and its enthusiasm for good research. Thank you!

We warmly thank all the patients and their families who accepted to take part in the project.

The work continues towards the study results. We can’t wait to share them with you!